Future Medical Device Companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Future Medical Device Companies

STXS 2.320

+1.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dr.praveen who wrote (17)	9/17/2006 6:50:51 PM
From: keokalani'nui	Read Replies (1) of 136

An existing medical device co, this could be an important product in a few years. Investors today have to take taxus stent risk however. Positive Preclinical Data on Vascular Wrap(TM) Presented at Vascular Conference Sunday September 17, 2:00 pm ET New Technology Has Potential to Improve Quality of Life for Hemodialysis Patients VANCOUVER, Sept. 17 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced positive preclinical data related to its Vascular Wrap(TM) paclitaxel-eluting mesh and Lifespan(R) graft technology platform at The Western Vascular Society 2006 Annual Meeting in La Jolla, California. snip The purpose of this preclinical study was to evaluate the effect of the Vascular Wrap(TM) bioabsorbable mesh containing paclitaxel on inhibiting neointimal hyperplasia in an animal model of dialysis access failure. In this study, neointimal hyperplasia was reduced by a minimum of 87.6% in animals who received a paclitaxel-eluting mesh compared with animals who received no mesh. snip Earlier in August, Angiotech announced the intent to launch a clinical trial in the United Kingdom to determine if hemodialysis patients who receive the Vascular Wrap paclitaxel-eluting mesh/Lifespan graft combination product experience fewer graft failures than those patients that receive the graft alone. Angiotech expects to enrol the first patient in the UK-based clinical trial this fall. The company also intends to conduct a similar trial in the U.S. Both trials are expected to be about 24 months in duration, with enrolment taking approximately one year. The goal of the studies is to provide Angiotech with sufficient data to submit to regulatory authorities for the approval to market the products in the United States and Europe.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next